常州(zhou)(zhou)千紅(hong)(hong)(hong)(hong)生(sheng)化制(zhi)藥股份有限(xian)公(gong)(gong)(gong)司(股票(piao)(piao)簡(jian)稱(cheng)(cheng):“千紅(hong)(hong)(hong)(hong)制(zhi)藥”,股票(piao)(piao)代碼:002550)前身是成立于(yu)1979年的(de)常州(zhou)(zhou)生(sheng)物化學廠,2011年2月(yue)18日在深(shen)圳證(zheng)券交易(yi)所中小板掛牌(pai)上市。目前旗下有江(jiang)蘇(su)眾紅(hong)(hong)(hong)(hong)生(sheng)物工程創藥研究院(yuan)有限(xian)公(gong)(gong)(gong)司(簡(jian)稱(cheng)(cheng):江(jiang)蘇(su)眾紅(hong)(hong)(hong)(hong))、江(jiang)蘇(su)晶(jing)紅(hong)(hong)(hong)(hong)生(sheng)物醫藥科技(ji)股份有限(xian)公(gong)(gong)(gong)司(簡(jian)稱(cheng)(cheng):晶(jing)紅(hong)(hong)(hong)(hong)生(sheng)科)、湖(hu)北(bei)潤紅(hong)(hong)(hong)(hong)生(sheng)物科技(ji)有限(xian)公(gong)(gong)(gong)司(簡(jian)稱(cheng)(cheng):湖(hu)北(bei)潤紅(hong)(hong)(hong)(hong))、常州(zhou)(zhou)英諾(nuo)升(sheng)康(kang)生(sheng)物醫藥科技(ji)有限(xian)公(gong)(gong)(gong)司(簡(jian)稱(cheng)(cheng):英諾(nuo)升(sheng)康(kang))等四家控股子(zi)公(gong)(gong)(gong)司。
公司是國(guo)(guo)內(nei)(nei)生(sheng)化制藥(yao)行業(ye)多糖(tang)類和(he)蛋(dan)白酶(mei)類藥(yao)品的(de)生(sheng)產(chan)經(jing)營企業(ye),現有(you)主要(yao)產(chan)品胰(yi)激肽原(yuan)酶(mei)系列(lie)、肝素鈉(na)及低分子肝素系列(lie)、復方消(xiao)化酶(mei)制劑(ji)、門冬酰胺酶(mei)系列(lie),生(sheng)產(chan)技術(shu)和(he)質量水平(ping)均(jun)已達(da)到(dao)國(guo)(guo)際(ji)、國(guo)(guo)內(nei)(nei)專業(ye)水平(ping)。公司主要(yao)品種的(de)內(nei)(nei)控質量標準(zhun)均(jun)被采(cai)納為(wei)國(guo)(guo)家標準(zhun),還參與國(guo)(guo)際(ji)藥(yao)品質量標準(zhun)修訂。多個產(chan)品分別通(tong)過美國(guo)(guo)、歐盟(meng)、日本等國(guo)(guo)家政府(fu)組織的(de)質量認(ren)證。
多年來(lai),公司(si)始(shi)終堅持科技創(chuang)(chuang)新(xin)(xin),堅持自主(zhu)研(yan)(yan)發與(yu)產學研(yan)(yan)合作(zuo),建立了(le)(le)完(wan)善的(de)產品研(yan)(yan)發和(he)成果(guo)轉化(hua)創(chuang)(chuang)新(xin)(xin)體系:以海歸(gui)人(ren)(ren)員為主(zhu)體的(de)創(chuang)(chuang)新(xin)(xin)藥(yao)物(wu)(wu)(wu)(wu)研(yan)(yan)究院、以適用人(ren)(ren)才為主(zhu)體的(de)成果(guo)轉化(hua)中心、以經驗豐(feng)富人(ren)(ren)士組成的(de)生產質量技術(shu)研(yan)(yan)究管理團(tuan)隊組成了(le)(le)“常州千紅(hong)國際(ji)生物(wu)(wu)(wu)(wu)醫藥(yao)創(chuang)(chuang)新(xin)(xin)藥(yao)物(wu)(wu)(wu)(wu)孵化(hua)基(ji)地”研(yan)(yan)發創(chuang)(chuang)新(xin)(xin)平臺(tai),平臺(tai)擁有近200名高素質人(ren)(ren)員,其中有10多名生物(wu)(wu)(wu)(wu)醫藥(yao)博(bo)士和(he)60多名碩士。2015年公司(si)收(shou)購的(de)小分子藥(yao)物(wu)(wu)(wu)(wu)創(chuang)(chuang)新(xin)(xin)平臺(tai)英(ying)諾升(sheng)康(kang),與(yu)江蘇眾紅(hong)擁有的(de)生物(wu)(wu)(wu)(wu)醫藥(yao)大分子研(yan)(yan)發平臺(tai)形(xing)成了(le)(le)互補與(yu)促進作(zuo)用,積極(ji)實現天(tian)然(ran)藥(yao)物(wu)(wu)(wu)(wu)向(xiang)基(ji)因工程藥(yao)物(wu)(wu)(wu)(wu)的(de)華麗轉身,為公司(si)未(wei)來(lai)健康(kang)、持續和(he)發展打(da)下良好(hao)的(de)戰略基(ji)礎。